Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial
Journal of Clinical Oncology · 10.11.2024 · 42 (32) · 3817-3825
DOI: 10.1200/jco.23.02626 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2024. Verfasst von Masataka Yagisawa und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Trastuzumab, Neoplasms, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE HERALD/EPOC1806 was conducted as a multicenter phase II trial assessing trastuzumab deruxtecan (T-DXd) therapy for patients with human epidermal growth factor receptor 2 ( HER2 )–amplified progressive stage solid tumors detected by cell-free DNA (cfDNA) testing. PATIENTS AND METHODS Patients exhibited advanced solid tumors with HER2 amplification that was identified via next-generation sequencing of cfDNA testing, without the requirement for immunohistochemical HER2 testing. The studied group was administered T-DXd at 5.4 mg/kg once every 3 weeks until onset of disease progression or intolerable toxicity. RESULTS Overall, 4,734 patients underwent cfDNA testing from December 2019 to January 2022, and 252 demonstrated HER2 amplification. Finally, the study included 62 patients with 16 cancer types with a median baseline plasma HER2 copy number (CN) of 8.55 (range, 2.4-73.9). Confirmed overall response rate (ORR) by investigator assessment was 56.5% (95% CI, 43.3 to 69.0), thus showing a value beyond the 5% threshold. Responses were evaluated for 13 cancer types, including KRAS -mutant colorectal (1/3), PIK3CA -mutant endometrial (5/6), and tissue HER2-negative gastric (1/2) cancers. Plasma HER2 CN above versus below the baseline median value did not differ for impact response; however, clearance of HER2 amplification in cfDNA on cycle 2 day 1 had higher response values compared with persistence. Median progression-free survival and response duration were 7.0 (95% CI, 4.9 to 9.7) and 8.8 (95% CI, 5.8 to 11.2) months, respectively, with the majority of complications being mild to moderate. Interstitial lung diseases were identified in 16 (26%) patients, including 14 patients with grade 1 disease, one patient with grade 2 disease, and one patient with grade 3 disease. CONCLUSION T-DXd treatment demonstrated high ORR with durable response in patients with advanced HER2 -amplified solid tumors determined with cfDNA testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Gastroenterology, Japan Community Health Care Organization Sapporo Hokushin Hospital, Sapporo, Japan.
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
- Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Osaka, Japan.
- Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki, Japan.
- Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
ORCID-Profile: Masataka Yagisawa, Hiroya Taniguchi, Taroh Satoh, Shigenori Kadowaki, Yu Sunakawa, Yoshito Komatsu, Daisuke Sakai, Ayako Doi, Takeshi Kajiwara, Satoshi Fujii, Shogo Nomura, Hideaki Bando, Takayuki Yoshino, Yoshiaki Nakamura
Zitieren
APA
Yagisawa, M., Taniguchi, H., Satoh, T., Kadowaki, S., Sunakawa, Y., Nishina, T., Komatsu, Y., Esaki, T., Sakai, D., Doi, A., Kajiwara, T., Ono, H., Asano, M., Hirano, N., Odegaard, J., Fujii, S., Nomura, S., Bando, H., Sato, A., …, & Nakamura, Y. (2024). Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial. Journal of Clinical Oncology, 42(32), 3817-3825. https://doi.org/10.1200/jco.23.02626
Vancouver
Yagisawa M, Taniguchi H, Satoh T, Kadowaki S, Sunakawa Y, Nishina T, et al. Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial. Journal of Clinical Oncology. 2024;42(32):3817-3825. doi:10.1200/jco.23.02626
BibTeX
@article{Yagisawa2024,
author = {Yagisawa, Masataka and Taniguchi, Hiroya and Satoh, Taroh and Kadowaki, Shigenori and Sunakawa, Yu and Nishina, Tomohiro and Komatsu, Yoshito and Esaki, Taito and Sakai, Daisuke and Doi, Ayako and Kajiwara, Takeshi and Ono, Hiromi and Asano, Masatoshi and Hirano, Nami and Odegaard, Justin and Fujii, Satoshi and Nomura, Shogo and Bando, Hideaki and Sato, Akihiro and Yoshino, Takayuki and Nakamura, Yoshiaki},
title = {Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {32},
pages = {3817--3825},
doi = {10.1200/jco.23.02626}
}
EUVIMED